BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33460483)

  • 1. Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; van Doorn PA; Bengrine T; van Rijs W; Baas F; Nagelkerke SQ; Kuijpers TW; Fokkink WR; Bunschoten C; Broers MC; Willemsen SP; Jacobs BC; Huizinga R
    Eur J Neurol; 2021 May; 28(5):1677-1683. PubMed ID: 33460483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; Hahn AF; Vermeulen M; Venance SL; van Doorn PA
    J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1331-6. PubMed ID: 25515502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations.
    Dalakas MC; Latov N; Kuitwaard K
    Expert Rev Neurother; 2022; 22(11-12):953-962. PubMed ID: 36645654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
    Eftimov F; Winer JB; Vermeulen M; de Haan R; van Schaik IN
    Cochrane Database Syst Rev; 2009 Jan; (1):CD001797. PubMed ID: 19160200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.
    Adrichem ME; Eftimov F; van Schaik IN
    J Peripher Nerv Syst; 2016 Sep; 21(3):121-7. PubMed ID: 27241239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
    Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
    Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.
    Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC
    Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
    Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
    Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
    Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
    Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
    Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
    J Peripher Nerv Syst; 2017 Dec; 22(4):425-432. PubMed ID: 29092099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional and unconventional therapies in typical and atypical chronic inflammatory demyelinating polyneuropathy with different clinical course of progression.
    Hung SKY; Hiew FL; Viswanathan S; Puvanarajah S
    J Peripher Nerv Syst; 2018 Sep; 23(3):183-189. PubMed ID: 30027593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
    Hughes R; Dalakas MC; Merkies I; Latov N; Léger JM; Nobile-Orazio E; Sobue G; Genge A; Cornblath D; Merschhemke M; Ervin CM; Agoropoulou C; Hartung HP;
    Lancet Neurol; 2018 Aug; 17(8):689-698. PubMed ID: 30001923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
    Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
    Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
    Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
    J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment options for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)].
    Kuntzer T
    Rev Neurol (Paris); 2006 Apr; 162(4):539-43. PubMed ID: 16585918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies.
    Tracy JA; Dyck PJ
    Curr Opin Neurol; 2010 Jun; 23(3):242-8. PubMed ID: 20389243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of transient axonal glycoprotein-1 in chronic inflammatory demyelinating polyneuropathy.
    Iijima M; Koike H; Katsuno M; Sobue G
    J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():52-5. PubMed ID: 21696500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
    Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
    Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.